A Single-armed, Open, Phase I Study of ReT01 ACT Injection in the Treatment of Patients With Advanced Solid Tumors
This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.
采用ReT01 ACT注射液治疗晚期实体瘤的单臂、开放Ⅰ期临床试验
主要目的:评价在晚期实体瘤受试者中输注ReT01 ACT注射液的耐受性和安全性,并确定最大耐受剂量(MTD)和/或II期推荐剂量(RP2D)。
次要目的:1、评价在晚期实体瘤受试者中输注ReT01 ACT注射液的药代动力学(PK)和药效学(PD)特征。2、初步评价在晚期实体瘤受试者中输注ReT01 ACT注射液的临床有效性。
100 项与 ReT01 ACT 相关的专利(医药)